These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9737823)

  • 1. Blood partition and protein binding of a new reversible proton pump inhibitor, YH1885.
    Han KS; Kim YG; Lee JW; Lee MG
    Biopharm Drug Dispos; 1998 Sep; 19(6):413-5. PubMed ID: 9737823
    [No Abstract]   [Full Text] [Related]  

  • 2. Determination of a new proton pump inhibitor, YH1885, in human plasma and urine by high-performance liquid chromatography.
    Han KS; Choi HC; Yoo JK; Lee JW; Lee MG
    J Chromatogr B Biomed Sci Appl; 1997 Aug; 696(2):312-6. PubMed ID: 9323554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats.
    Han KS; Kim YG; Yoo JK; Lee JW; Lee MG
    Biopharm Drug Dispos; 1998 Nov; 19(8):493-500. PubMed ID: 9840211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers.
    Li H; Chung SJ; Kim DC; Kim HS; Lee JW; Shim CK
    Drug Metab Dispos; 2001 Jan; 29(1):54-9. PubMed ID: 11124230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers.
    Yu KS; Bae KS; Shon JH; Cho JY; Yi SY; Chung JY; Lim HS; Jang IJ; Shin SG; Song KS; Moon BS
    J Clin Pharmacol; 2004 Jan; 44(1):73-82. PubMed ID: 14681344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of homopyrimidazole derivatives with biopolymers. I. Binding of MZ 144, a new potent analgesic to human serum albumin.
    Szekerke M; Horváth M
    Arzneimittelforschung; 1975 Jul; 25(7):1016-21. PubMed ID: 241355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential inhibitory effect of revaprazan, an acid pump antagonist, on anticoagulation with warfarin.
    Jung JW; Kang HR; Kwon JW; Kim TE; Lee SH; Hong KS; Yu KS; Cho SH
    Tohoku J Exp Med; 2011 Aug; 224(4):293-300. PubMed ID: 21799301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Proton Pump Inhibitor's Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study.
    Jo Y; Park E; Ahn SB; Jo YK; Son B; Kim SH; Park YS; Kim HJ
    Gut Liver; 2015 Sep; 9(5):607-14. PubMed ID: 25473078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imidazole binding to human serum albumin.
    Rodrigo MC; Ceballos A; Mariño E; Cachaza JM; Domínguez-Gil A; Kuemmerle HP
    Int J Clin Pharmacol Ther Toxicol; 1988 Jun; 26(6):320-2. PubMed ID: 3410610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrahydroisoquinolines and beta-carbolines: specific binding to human platelet alpha 2-receptors in vitro.
    Given MB; Longenecker GL
    Res Commun Chem Pathol Pharmacol; 1983 Aug; 41(2):349-52. PubMed ID: 6314454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetrahydroisoquinolines and the catecholamine-binding granules of the adrenal medulla.
    Greenberg RS; Cohen G
    Eur J Pharmacol; 1972 May; 18(2):291-4. PubMed ID: 5037389
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacokinetic studies on dauricine].
    Hou SX; Dai ZS; Wang FJ; Guo LJ; Hu CJ
    Yao Xue Xue Bao; 1982 Nov; 17(11):863-5. PubMed ID: 7168337
    [No Abstract]   [Full Text] [Related]  

  • 13. [Study of the absorption of a new peripheral vasodilator (CH-141) by in vitro and in vivo methods. I. In vitro model of liquid transport].
    Szemere L; Marton S
    Acta Pharm Hung; 1985 Mar; 55(2):59-67. PubMed ID: 4013755
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative binding studies of anticonvulsant drugs to bovine serum albumin.
    Dal Pozzo A; Acquasaliente M; Tajana A
    Farmaco Sci; 1983 Aug; 38(8):609-18. PubMed ID: 6617856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and preliminary activity evaluation of novel pyrimidine derivatives as acid pump antagonists.
    Song W; Zhang X; Li S; Xu W
    Chem Biol Drug Des; 2015 Mar; 85(3):306-14. PubMed ID: 24995399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of Merocyanine 540 with serum albumins: photophysical and binding studies.
    Banerjee M; Pal U; Subudhhi A; Chakrabarti A; Basu S
    J Photochem Photobiol B; 2012 Mar; 108():23-33. PubMed ID: 22264940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability, blood partition and plasma protein binding of ipriflavone, an isoflavone derivative.
    Kim SH; Lee JS; Lee MG
    Biopharm Drug Dispos; 1999 Oct; 20(7):355-60. PubMed ID: 10760844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability, blood partition, and pharmacokinetics of a new reversible proton pump inhibitor, YJA-20379-1.
    Kim SH; Han KS; Choi WS; Chang MS; Lee MG
    Res Commun Mol Pathol Pharmacol; 1997 Oct; 98(1):77-84. PubMed ID: 9434317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergism between a phosphodiesterase inhibitor and modulators of thromboxane formation on thrombin-induced sudden death in rabbits.
    Smith EF; Olson RW
    Prog Clin Biol Res; 1987; 242():241-6. PubMed ID: 3671385
    [No Abstract]   [Full Text] [Related]  

  • 20. Designed inhibitors with hetero linkers for gastric proton pump H
    Jana K; Bandyopadhyay T; Ganguly B
    J Mol Graph Model; 2017 Nov; 78():129-138. PubMed ID: 29055186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.